AKRO
- Akero Therapeutics, Inc.
()
Overview
Company Summary
Akero Therapeutics, Inc. (AKRO) is a biopharmaceutical company that focuses on developing and commercializing innovative therapeutics to treat serious metabolic diseases and non-alcoholic steatohepatitis (NASH).
NASH is a progressive form of non-alcoholic fatty liver disease (NAFLD), which is characterized by the accumulation of fat in the liver, leading to inflammation and potential liver damage. It is a significant and growing public health concern due to its association with obesity, diabetes, and other metabolic disorders.
Akero Therapeutics aims to address this unmet medical need by leveraging its deep understanding of the underlying biology and physiology of NASH and related metabolic disorders. Their key focus is on developing novel drugs that target the specific mechanisms involved in NASH pathogenesis.
The company's leading drug candidate is AKR-001, a long-acting fibroblast growth factor 21 (FGF21) analog. FGF21 is a naturally occurring hormone that regulates various metabolic processes, including lipid metabolism, glucose homeostasis, and insulin sensitivity. AKR-001 is designed to mimic the effects of endogenous FGF21, potentially reducing liver fat, inflammation, and fibrosis in patients with NASH.
Akero Therapeutics also conducts extensive research to further understand the underlying mechanisms of NASH and explore potential therapeutic targets. Through their comprehensive approach, the company aims to provide much-needed treatment options for patients with NASH, a disease with limited approved therapies currently available.
In summary, Akero Therapeutics focuses on developing innovative therapeutics to treat serious metabolic diseases, with a primary emphasis on addressing the unmet medical need for effective treatments for NASH. They aim to provide novel drugs that target the underlying mechanisms of this condition, potentially improving patient outcomes and quality of life.